Relay Therapeutics公司发布了其药物Zovegalisib的初步临床数据,表明该药物在针对由Pik3CA基因驱动的血管异常患者群体中,展现出具有差异化优势的安全性和疗效前景。这些早期数据提示,Zovegalisib可能为该患者群体提供一种新的潜在治疗选择。
Relay Therapeutics公司发布了其药物Zovegalisib的初步临床数据,表明该药物在针对由Pik3CA基因驱动的血管异常患者群体中,展现出具有差异化优势的安全性和疗效前景。这些早期数据提示,Zovegalisib可能为该患者群体提供一种新的潜在治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.